Efficacité et innocuité du mirikizumab chez les patients atteints de psoriasis en plaques modéré à sévère : résultats à 104 semaines d'une étude randomisée de phase 2
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Messages clés
- Une réponse de haut niveau au mirikizumab jusqu'à 2 ans peut être obtenue et maintenue.
- De nombreux patients qui n'atteignent pas le PASI 90/100 au cours des 16 premières semaines de traitement au mirikizumab peuvent atteindre et maintenir une réponse de haut niveau avec la poursuite du traitement.
- De nombreux patients qui atteignent PASI 90/100 au cours des 16 premières semaines de traitement au mirikizumab peuvent maintenir une réponse de haut niveau avec traitement PRN.
Presenting Author
Robert Bissonnette, MD, FRCPC
Founder and CEO, Innovaderm Research
Board certified in dermatology, Dr. Robert Bissonnette is the president and founder of Innovaderm Research, a CRO specializing in the design, conduct and analysis of clinical trials in various areas of dermatology. He has published more than 185 articles and book chapters and gives lectures on various aspects of Dermatology at various national and international meetings.
Dr. Bissonnette earned his medical degree from the University of Montreal. He completed his residency training in dermatology at the University of Montreal and completed his basic and clinical research training at McGill University and the University of British Columbia. He was an Associate Professor of dermatology at the University of Montreal until 2004.
Author disclosures
R Bissonnette is an Advisory Board Member, Consultant, Speaker, Investigator for, and/or received honoraria or grants from, AbbVie, Almirall, Arcutis, Arista, Bausch Health/Valeant, Boehringer Ingelheim, Boston Pharma, Bristol-Myers Squibb, Dermavant, Eli Lilly, Escalier, Janssen, Kineta, Kyowa Kirin, LEO Pharma, Pfizer, Regeneron, Sienna and UCB. R Bissonnette is also an employee and shareholder of Innovaderm Research.
